Regulatory Affairs
How to Build a Powerful Personal Brand in Pharma Without Sharing Proprietary Data
A complete step-by-step guide for pharmaceutical, biotech and life science professionals on building a credible, visible personal brand on LinkedIn - without ever crossing compliance lines or risking proprietary data exposure. Covers brand strategy, content pillars, storytelling frameworks, and the exact boundaries every pharma professional must respect.
LinkedIn
How to Highlight Regulatory Affairs and Compliance Expertise on Your LinkedIn Profile
A detailed step-by-step LinkedIn guide for Regulatory Affairs Specialists, Quality Assurance professionals, Pharmacovigilance Officers, CMC Scientists, and all pharmaceutical compliance professionals. Learn exactly how to frame your regulatory expertise on LinkedIn to attract the right roles, visibility, and recognition - without exposing proprietary submissions or confidential regulatory strategy.
Industry
U.S. Initiates Tariff Probe into Germany’s Pharmaceutical Pricing Policies
The United States has formally launched a trade investigation under Section 301 into Germany’s drug reimbursement practices, citing concerns that domestic price controls unfairly burden American innovation.
Biotechnology
Global Biopharma Layoff Tracker Report (2025-2026): A Structural Reshaping
A detailed global report analyzing major pharmaceutical and biotech layoffs across the US, EU, and India from 2025 to 2026, including strategic shifts by enGene, Takeda, Bayer, and BioNTech.
Biotechnology
Global Pharma Giants Pledge $500 Billion in U.S. Investments
Drugmakers such as Eli Lilly, Pfizer, AstraZeneca, and Roche have collectively announced approximately $500 billion in U.S. investments aimed at strengthening infrastructure and reducing supply-chain vulnerabilities.
Pharmaceutical
The Cascade Effect: How US MFN and IRA Pricing Mandates Are Reshaping Drug Development, Launch Sequencing, and Ireland’s Life Sciences Sector
An in-depth analysis of how US Most Favored Nation (MFN) drug pricing proposals and the Inflation Reduction Act (IRA) are forcing pharmaceutical companies to restructure indication sequencing, ex-US launches, and global supply chains.
Pharmaceutical
Eisai Allocates £48M to UK Cold-Chain Pharma Packaging Hub
Japanese pharmaceutical company Eisai announces a £48 million investment at its Hatfield, UK site to establish advanced cold-chain supply and packaging capabilities, supported by the Life Sciences Innovative Manufacturing Fund.
Industry
Beyond the Strait: How the US-Iran Peace Deal Will Reshape Ireland’s Pharmaceutical Value Chains in 2026
With the US-Iran peace deal signed and the Strait of Hormuz set to reopen, Ireland's pharmaceutical export sector stands to benefit from stabilized global energy tariffs, normalized maritime trade corridors, and renewed multinational capital inflows.
Regulatory Affairs
How Most Favored Nation (MFN) Pricing Impacts Drug Development & Launch Planning
An expert analysis of the strategic shifts required in global drug development, indication sequencing, and launch timelines in response to proposed Most Favored Nation pricing and the Inflation Reduction Act.
Industry
Ireland Announces Major Updates to Employment Permit Occupation Lists
A detailed analytical deep-dive into the Irish Government's 2026 updates to Critical Skills and General Employment Permit lists, reviewing quotas, key sectors, and the proposed changes to the 50:50 rule.
Industry
AbbVie Nears $11 Billion Acquisition of Apogee Therapeutics to Bolster Immunology Pipeline
AbbVie is reportedly in advanced negotiations to acquire clinical-stage biotech Apogee Therapeutics for approximately $10.9 billion in cash, aiming to secure the promising long-acting eczema therapy zumilokibart.
Industry
Laprophan Accelerates International Expansion with Completion of Rivopharm Acquisition in Switzerland
Moroccan pharmaceutical group Laprophan finalizes its acquisition of a controlling stake in Swiss pharmaceutical firm Rivopharm, securing a strategic industrial base in Europe and expanding its global footprint.